Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-246.49%
operating margin TTM
-240.74%
revenue TTM
31.47 Million
revenue per share TTM
0.27$
valuation ratios | |
|---|---|
| pe ratio | -48.06 |
| peg ratio | -13.22 |
| price to book ratio | 12.59 |
| price to sales ratio | 119.98 |
| enterprise value multiple | -54.09 |
| price fair value | 12.59 |
profitability ratios | |
|---|---|
| gross profit margin | 98.45% |
| operating profit margin | -240.74% |
| pretax profit margin | -246.49% |
| net profit margin | -246.49% |
| return on assets | -17.62% |
| return on equity | -31.61% |
| return on capital employed | -18.8% |
liquidity ratio | |
|---|---|
| current ratio | 10.96 |
| quick ratio | 10.96 |
| cash ratio | 5.61 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 0.00 |
| days of payables outstanding | 2,898.80 |
| cash conversion cycle | -2,898.80 |
| receivables turnover | 0.00 |
| payables turnover | 0.13 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.26 |
| debt equity ratio | 0.39 |
| long term debt to capitalization | 0.26 |
| total debt to capitalization | 0.28 |
| interest coverage | -15.40 |
| cash flow to debt ratio | -0.69 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.70 |
| cash per share | 3.48 |
| operating cash flow per share | -0.70 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | -0.69 |
| short term coverage ratios | -7.89 |
| capital expenditure coverage ratio | -315.85 |
Frequently Asked Questions
When was the last time CymaBay Therapeutics, Inc. (NASDAQ:CBAY) reported earnings?
CymaBay Therapeutics, Inc. (CBAY) published its most recent earnings results on 28-02-2024.
What is CymaBay Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. CymaBay Therapeutics, Inc. (NASDAQ:CBAY)'s trailing twelve months ROE is -31.61%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. CymaBay Therapeutics, Inc. (CBAY) currently has a ROA of -17.62%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did CBAY's net profit margin stand at?
CBAY reported a profit margin of -246.49% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is CBAY's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 10.96 in the most recent quarter. The quick ratio stood at 10.96, with a Debt/Eq ratio of 0.39.